Approaches to abrogate the poor outcomes associated with high-risk disease are needed and include
maximising depth of response following induction and intensifying maintenance therapy. As
demonstrated above data from the EMN02 and STaMINA trials to support the use of tandem autograft
in high-risk patients aiming to maximise depth of response and prolong first remission.
References:
1. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with
Transplantation for Myeloma. N Engl J Med 2017; 376(14): 1311-20.
2. Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by
autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III
GMMG-HD2 trial. Br J Haematol 2016; 173(5): 731-41.
3. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus
bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone
consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma
(EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 2020.
4. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous Transplantation, Consolidation, and
Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol 2019; 37(7):
589-97.
5. Hari P, Pasquini M, Stadtmauer EA, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of
postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of
multiple myeloma (MM). Journal of Clinical Oncology; 2020.
6. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and
dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;
136(8): 936-45.
7. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without
daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple
myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019; 394(10192): 29-38.